[Reuters] – A new hepatitis C drug made by Johnson & Johnson showed an acceptable safety profile in clinical trials, reviewers for the U.S. Food and Drug Administration said on Tuesday. The drug, simeprevir, was tested …
Read more on this.
Johnson & Johnson (JNJ), valued at $260.31B, opened at $91.53.
Looking at the stock, its one day range is $91.50 to $92.42 with the price of the stock fluctuating between $68.51 to $94.42 over the last 52 weeks.
Priced at 16.64x this year’s forecasted earnings, JNJ shares are relatively expensive compared to the industry’s 7.41x forward p/e ratio.
The company pays shareholders $2.64 per share annually in dividends, yielding 2.90%.
In a review of the consensus earnings estimate this quarter, 16 sell-side analysts are looking at $1.20 per share, which would be $0.01 better than the year-ago quarter and a $0.02 sequential decrease. What we find to be interesting is that the full-year EPS estimate of $5.48 is a $0.38 better when compared to the previous year’s annual results.
The quarterly earnings estimate is predicated on a consensus revenue forecast of $17.93 Billion. If reported, that would be a 2.11% increase over the year-ago quarter.
Deutsche Bank downgraded JNJ from Buy to Hold (Jul 17, 2013).
Previously, Deutsche Bank upgraded JNJ from Hold to Buy.
When considering if the stock is under or overvalued, the average price target is $94.50, which is 3.24% above where the stock opened this morning.
Johnson & Johnson (NYSE:JNJ), together with its subsidiaries, engages in the research and development, manufacture and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics.
Tag Helper ~ Stock Code: JNJ | Common Company name: Johnson & Johnson | Full Company name: Johnson & Johnson (NYSE:JNJ) .